Testmate Health closes CHF1.6 million seed financing round

Please login or
register
21.10.2021
Testmate App

The mission of Testmate Health is to put people in charge of their own sexual health by making accurate testing of sexually transmitted diseases easy and accessible with an at-home test. With the funds, the start-up plans to accelerate product development and complete pre-clinical studies of their device.

Testmate Health has successfully closed an oversubscribed seed round of CHF 1,6 million, with the first closing occurring earlier this spring and the round extended to bring in U.S. based & women's health focused VC Rhia Ventures. In addition to Rhia Ventures, Next Ventures for Humanity and several business angels participated in the financing round. These include medtech experts and investors such as Thomas Zehnder, serial entrepreneurs including Switzerland's "Dragons’ Den" investor Tobias Reichmuth, founders of sexual wellness e-commerce platform Amorana Alan Frei and Lukas Speiser. In a blog post on LinkedIn the team comments: “We are privileged to have on board such talented individuals who will advise Testmate Health through the next key stages leading up to commercialisation.”

Thomas Zehnder will join Testmate’s Board of Directors and Elizabeth Bailey, Managing Director Rhia Ventures, will become Board Observer. In their blog post the team states: “With their deep MedTech industry expertise across both sides of the Atlantic, we are privileged to have them guide Testmate Health through the next stages.”

With the funds, the start-up plans to accelerate product development & complete pre-clinical studies of their device. Testmate Health’s rapid digital test will for the first time, provide customers with an option for direct at-home self-testing for common sexually transmitted diseases (STD) with immediate results. The award-winning spin-off of University of Geneva gives customers the choice of a hassle-free, simple, easy-to-use immediate urine self-test that enables prompt detection of the for most common STDs: chlamydia, gonorrhoea, trichomoniasis and mycoplasma genitalium. Customers can skip the visit to a clinic and don’t have to wait days for a result. Results are scanned and uploaded to a paired app to guide patients towards appropriate follow-up if necessary.

(SK)

0Comments

rss